F6Publishing

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Articles Published Processes

Keyword: Boceprevir

Page 1 of 1 ( 11 items )
<<
1
>>

1	Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection 4/13/2017 3:45:15 PM \| Browse: 1505 \| Download: 3013
2	Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection 2/6/2017 9:08:00 AM \| Browse: 1226 \| Download: 2827
3	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience 8/3/2016 8:11:00 AM \| Browse: 1816 \| Download: 3161
4	Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia 2/22/2016 3:38:00 PM \| Browse: 1506 \| Download: 3135
5	Chronic hepatitis C: This and the new era of treatment 1/15/2016 9:49:00 AM \| Browse: 1843 \| Download: 1992
6	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients 12/2/2015 12:20:00 PM \| Browse: 1893 \| Download: 2268
7	Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection 8/29/2015 5:11:00 PM \| Browse: 1153 \| Download: 1972
8	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens 6/29/2015 4:40:00 PM \| Browse: 1526 \| Download: 2920
9	Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings 2/11/2015 5:56:00 PM \| Browse: 1669 \| Download: 2448
10	Telaprevir/boceprevir era: From bench to bed and back 9/16/2014 8:07:00 PM \| Browse: 1693 \| Download: 2015
11	Grade 4 febrile neutropenia and Fournier’s Syndrome associated with triple therapy for hepatitis C virus: A case report 8/26/2014 2:42:00 PM \| Browse: 1383 \| Download: 1613

Page 1 of 1 ( 11 items )
<<
1
>>

Write to the Help Desk

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.